Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Malignant Neoplasm
70%
Maximum Tolerated Dose
69%
Adverse Event
39%
Anticancer Drug
37%
Immunotherapy
37%
Breast Cancer
28%
Progression Free Survival
27%
Bortezomib
27%
Tolerability
26%
Diseases
25%
Chemotherapy
25%
Emphysema
20%
Combination Therapy
18%
Disease Exacerbation
17%
Anticarcinogen
16%
Neuropathy
14%
Neoplasm
14%
Metastatic Uvea Melanoma
13%
Overall Survival
11%
Cabazitaxel
9%
Cisplatin
9%
Erlotinib
8%
Drug Development
8%
Taxane
8%
Cytotoxic Chemotherapy
7%
Triple Negative Breast Cancer
7%
Sotrastaurin
6%
Alpelisib
6%
Propranolol
6%
Fibronectin
6%
Venous Thromboembolism
6%
Premature Labor
6%
Lymph Vessel Metastasis
6%
Placebo
6%
Sitravatinib
6%
Dedifferentiated Liposarcoma
6%
Diffuse Large B Cell Lymphoma
6%
Pexidartinib
6%
Malignant Peripheral Nerve Sheath Tumor
6%
Coronavirinae
6%
Phase II Trials
6%
Phase I Trials
6%
Metformin
6%
Metastatic Colorectal Cancer
6%
Drug Administration
6%
Rituximab
6%
Rapamycin
6%
Transitional Cell Carcinoma
6%
Ruxolitinib
6%
Medicine and Dentistry
Clinical Trial
74%
Emphysema
48%
Breast Cancer
44%
Malignant Neoplasm
40%
Lung
33%
Diseases
25%
Overall Survival
24%
Pneumonectomy
23%
Chronic Obstructive Pulmonary Disease
22%
COVID-19
20%
Anticancer Drug
20%
Adverse Event
19%
Reproducibility
18%
Targeted Therapy
17%
Neoplasm
16%
Patient-Reported Outcome
14%
Checklist
13%
DLCO
13%
Oncology
12%
Quality of Life
11%
Cisplatin
11%
Radiation Therapy
11%
Walking Distance
11%
Immunotherapy
11%
Metastatic Carcinoma
11%
Six Minute Walk Test
11%
Drug Prescription
10%
Triple Negative Breast Cancer
10%
Surgeon
10%
Breast Tumor
10%
Progression Free Survival
10%
Protein Kinase B
9%
Breathing
9%
Combination Therapy
8%
Diffusing Capacity
8%
Neoadjuvant Chemotherapy
8%
Odds Ratio
8%
Disease Exacerbation
8%
Recurrent Disease
8%
Clinician
7%
Hormone Therapy
7%
Metastatic Breast Cancer
7%
Carbon Monoxide
7%
Survival Rate
7%
Lymph Node Metastasis
7%
Anticarcinogen
6%
Exercise Test
6%
Lumpectomy
6%
Venous Thromboembolism
6%
Cerebrospinal Fluid
6%
Nursing and Health Professions
Emphysema
30%
Adverse Event
14%
Obstructive Lung Disease
13%
Walking Distance
13%
Lung Resection
10%
Combination Therapy
10%
Dose Calculation
9%
National Health Organization
9%
Confidence Interval
8%
Reproducibility
8%
Cancer Therapy
8%
Malignant Neoplasm
7%
Fibronectin
6%
Lung Fibrosis
6%
Metastatic Breast Cancer
6%
Pulmonary Rehabilitation
6%
Pachymetry
6%
Radiologist
6%
Spirometry
6%
Cryotherapy
6%
Neuropathy
6%
Breast Cancer
6%
Compression Therapy
6%
Carbon Monoxide
6%
Central Corneal Thickness
6%
Premature Labor
6%
Placebo
6%
Artificial Tear
6%
Reflectometry
6%
Randomization
6%
Diseases
6%
Obstruction
5%
Practice Guideline
5%
Votre message a été envoyé avec succès.
Votre message n’a pas été envoyé en raison d’une erreur.
